Vigabatrin (Epilepsy) updated on 04-22-2025

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)8.16 [1.80, 37.01]0%4 studies12513not evaluable ROB15.80 [3.00; .]
Major congenital malformations8.16 [1.80, 37.01]0%4 studies12513not evaluable ROB15.80 [3.00; .]
Microcephaly / Small head circumference for gestational age1.81 [0.10, 31.40]-1 study6999not evaluable ROB-
Congenital heart defects12.98 [0.62, 271.33]-1 study46not evaluable ROB-
Digestive system anomalies16.71 [0.77, 363.61]-1 study36not evaluable ROB-
Hypospadias8.96 [0.45, 179.29]-1 study66not evaluable ROB-
Limb defects23.44 [1.00, 547.07]-1 study26not evaluable ROB46.37 [1.07; .]
Neural Tube Defects39.12 [1.43, 1070.14]-1 study16not evaluable ROB77.74 [2.21; .]
Oro-facial clefts39.12 [1.43, 1070.14]-1 study16not evaluable ROB77.74 [2.21; .]

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Low birth weight (< 2500g)1.24 [0.07, 21.50]-1 study1,0069not evaluable ROB-
Small for gestational age (weight)0.48 [0.03, 8.36]-1 study2,4169not evaluable ROB-

Hide endpoints reported in only one study ...